* IGM Biosciences Inc reported a quarterly adjusted loss of 83 cents per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of $-1.33. The mean expectation of nine analysts for the quarter was for a loss of 83 cents per share. Wall Street expected results to range from -96 cents to -75 cents per share.
* Revenue fell 4.8% to $497.00 thousand from a year ago; analysts expected $759.38 thousand.
* IGM Biosciences Inc's reported EPS for the quarter was a loss of 83 cents.
* The company reported a quarterly loss of $49.82 million.
* IGM Biosciences Inc shares had risen by 4.9% this quarter and gained 21.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 11.9% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for IGM Biosciences Inc is $20.00 This summary was machine generated from LSEG data May 10 at 11:59 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.83 -0.83 Met
Dec. 31 2023 -1.03 -1.01 Beat
Sep. 30 2023 -1.21 -1.04 Beat
Jun. 30 2023 -1.43 -1.43 Met
Comments